Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Thermo Fisher Scientific Inc. (TMO) — XLV Health Care · S&P 500 Profile |賽默飛世爾科技公司介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Thermo Fisher Scientific Inc. (TMO) — Business, History & S&P 500 Profile | 賽默飛世爾科技公司介紹

Thermo Fisher Scientific Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #45 · 賽默飛世爾科技公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 28, 2026 (ET) close
Financials: FY2024
MARKET CAP
$260.36B
Oct 28, 2026 close
S&P 500 WEIGHT
0.37%
Rank #45 · Oct 28, 2026
SECTOR RANK
#6
Health Care · Oct 28, 2026
S&P 500 RANK
#45
0.37% · Oct 28, 2026

SNAPSHOT

TickerTMO
CompanyThermo Fisher Scientific Inc.
GICS sector / industryHealth Care (XLV) / Life Sciences Tools & Services
S&P 500 rank (by weight)#45 · 0.37% (Oct 28, 2026)
Sector rank#6 in Health Care (Oct 28, 2026)
HeadquartersWaltham, Massachusetts
Founded1956
CEOMarc N. Casper (Chairman, President and CEO)
EmployeesApproximately 125,000 (FY2024)
Market cap$260.36B (Oct 30, 2026)
Share price$697.00 (Oct 30, 2026 close)
SEC filingsEDGAR — CIK 0000097745

WHAT IT DOES

Thermo Fisher Scientific supplies the tools and services behind life sciences research, drug development and clinical diagnostics. Its one-line model: sell instruments, reagents and consumables, and run the laboratory and pharma services that turn them into results.

Revenue comes from products used in research and production and from services including contract development, manufacturing and clinical research. Customers are pharmaceutical and biotechnology companies, academic and government laboratories, hospitals and industrial users.

The economics mix recurring consumables with capital equipment: instruments are lumpy, while reagents, service contracts and outsourced pharma work recur, so the blend steadies revenue through research funding cycles.

BUSINESS SEGMENTS

Life Sciences SolutionsReagents, instruments and consumables for biological and medical research, drug discovery and production.
Analytical InstrumentsInstruments, consumables, software and services for pharmaceutical, biotechnology, academic, government and industrial markets.
Specialty DiagnosticsClinical diagnostics products including immunodiagnostics, microbiology and transplant diagnostics.
Laboratory Products and Biopharma ServicesLaboratory equipment, research and safety market channels, and pharma services and clinical research.

HISTORY

YearMilestone
1956Thermo Electron is founded.
2006Thermo Electron merges with Fisher Scientific to form Thermo Fisher Scientific.
2024Thermo Fisher completes the acquisition of Olink, a proteomics solutions provider.

COMPETITIVE POSITION

  • Breadth across instruments, reagents and services, so a customer can equip and run a laboratory from one supplier.
  • Scale in manufacturing and distribution for consumables that must arrive reliably and at volume.
  • Recurring revenue from reagents, service contracts and outsourced pharma work that cushions instrument cycles.
  • Competition set: Danaher, Agilent Technologies, Waters and Avantor, each strong in different tools and services.
  • Acquisition capacity: a record of buying adjacent tools and services and folding them into a common channel.

FINANCIAL SNAPSHOT

Total revenue$44.56B (FY2025 revenues)
Operating income$7.75B (FY2025 GAAP operating income)
Net income$6.70B (FY2025 GAAP net income attributable)
Diluted EPS$17.74 (FY2025 GAAP diluted EPS)
Source: Thermo Fisher Scientific 2025 results release and 2025 Form 10-K (total revenue $44.56B; operating income $7.75B; net income $6.70B; diluted EPS $17.74).

KEY RISKS

  • Research funding cycles in academia, government and biopharma that move instrument demand.
  • Biopharma customer concentration and outsourcing decisions that shift service volumes.
  • Pricing pressure on instruments and diagnostics from large buyers and competitors.
  • Integration risk from acquisitions, including goodwill and restructuring costs.
  • Regulatory and trade exposure across a global manufacturing and distribution network.

WHY IT MATTERS FOR THE S&P 500

Thermo Fisher Scientific is a mid-weight health care constituent: rank #45 by weight at 0.37% as of Oct 28, 2026, and #6 in Health Care. Its orders and service volumes are read as a gauge of life sciences research spending, and through it of drug development activity across the sector.

SOURCES & METHODOLOGY

Financials, segments, headquartersThermo Fisher Scientific 2024 results release (January 30, 2025) and 2024 Form 10-K
Index weight & ranksSlickcharts S&P 500 weights, Oct 28, 2026 close, fetched Oct 29, 2026
Market cap$260.36B (Oct 30, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

TMO

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號TMO
公司Thermo Fisher Scientific(賽默飛世爾科技)
GICS 板塊/行業醫療保健(XLV)/生命科學工具與服務
標普500排名(按權重)#45 · 0.37%(Oct 28, 2026)
板塊內排名醫療保健 #6(Oct 28, 2026)
總部美國麻薩諸塞州沃爾姆
成立1956年
執行長Marc N. Casper(董事長兼總裁兼執行長)
員工約 125,000 人(2024 年)
市值$260.36B(Oct 30, 2026)
股價$697.00(Oct 30, 2026 收盤)
SEC 申報EDGAR — CIK 0000097745

業務概覽

Thermo Fisher Scientific 提供生命科學研究、藥物開發與臨床診斷背後的工具與服務。其一句話商業模式是:售賣儀器、試劑與耗材,並運營將其轉化為成果的實驗室與藥品服務。

收入來自研究與生產用產品與服務,包括委託開發、製造與臨床研究。客戶為藥品與生物技術公司、學術與政府實驗室、醫院與工業用戶。

這種經濟混合經常性耗材與資本設備:儀器訂單波動大,而試劑、服務合約與外包藥品工作反覆發生,故組合可在研究經費週期中穩定收入。

業務板塊

生命科學方案生物與醫學研究、藥物發現與生產的試劑、儀器與耗材。
分析儀器藥品、生物技術、學術、政府與工業市場的儀器、耗材、軟體與服務。
專業診斷臨床診斷產品,包括免疫診斷、微生物學與移植診斷。
實驗室產品與生物醫藥服務實驗室設備、研究與安全市場通路、藥品服務與臨床研究。

歷史沿革

年份里程碑
1956Thermo Electron 成立。
2006Thermo Electron 與 Fisher Scientific 合併,組成 Thermo Fisher Scientific。
2024Thermo Fisher 完成收購蛋白質組學方案提供商 Olink。

競爭地位

  • 儀器、試劑與服務的廣度:客戶可從單一供應商配備與運營實驗室。
  • 耗材製造與配送的規模:耗材必須可靠且大量到貨。
  • 試劑、服務合約與外包藥品工作帶來的經常性收入,可緩衝儀器週期。
  • 競爭集合:Danaher、Agilent Technologies、Waters 與 Avantor,各家在不同工具與服務中具優勢。
  • 收購能力:持續收購相鄰工具與服務並整合入共同通路的紀錄。

財務快照

總收入$44.56B(FY2025 收入)
營業利潤$7.75B(FY2025 GAAP 營業利潤)
淨利潤$6.70B(FY2025 GAAP 歸屬淨利潤)
稀釋 EPS$17.74(FY2025 GAAP 稀釋 EPS)
來源:Thermo Fisher Scientific 2025 年業績發佈及 2025 年 Form 10-K(總收入 445.6 億美元;營業利潤 77.5 億美元;淨利潤 67.0 億美元;稀釋 EPS 17.74 美元)。

主要風險

  • 學術、政府與生物藥品研究經費週期影響儀器需求。
  • 生物藥品客戶集中與外包決策改變服務量。
  • 大型買家與競爭對手對儀器與診斷產品的價格壓力。
  • 收購整合風險,包括商譽與重組成本。
  • 全球製造與配送網絡的監管與貿易暴露。

對標普500的重要性

Thermo Fisher Scientific 是權重中等的醫療保健成分股:按權重排名 #45,權重 0.37%(以 Oct 28, 2026 為準),醫療保健板塊內排名 #6。其訂單與服務量被視為生命科學研究支出的指標,並由此反映整個板塊的藥物開發活動。

來源與方法

財務、板塊、總部Thermo Fisher Scientific 2024 年業績發佈(2025 年 1 月 30 日)及 2024 年 Form 10-K
指數權重與排名Slickcharts S&P 500 權重,Oct 28, 2026 收盤,Oct 29, 2026 抓取
市值$260.36B(Oct 30, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

TMO

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · TMO
Data as of Oct 28, 2026 · Financials FY2024 (10-K) · Market data Oct 2026
Previous · Wells Fargo & Company (WFC) — XLF Financials · S&P 500 Profile |富國銀行公司介紹Next · RTX Corporation (RTX) — XLI Industrials · S&P 500 Profile |RTX 公司介紹

Entered 2026-10-29 17:26 · updated 2026-11-15 00:08 · rev 11